|
JPS6357096A
(ja)
*
|
1986-08-29 |
1988-03-11 |
工業技術院長 |
紐体切断装置
|
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
|
US6001968A
(en)
*
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
|
EP0736599A3
(en)
*
|
1995-04-03 |
1996-12-11 |
Takeda Chemical Industries Ltd |
The rat obesity gene, its gene product and its production
|
|
US5614379A
(en)
*
|
1995-04-26 |
1997-03-25 |
Eli Lilly And Company |
Process for preparing anti-obesity protein
|
|
US5840517A
(en)
*
|
1995-04-26 |
1998-11-24 |
Eli Lilly And Company |
Process for preparing obesity protein analogs
|
|
ZA963530B
(en)
*
|
1995-05-05 |
1996-11-05 |
Hoffmann La Roche |
Recombinant obese (ob) proteins
|
|
EP0741187A2
(en)
*
|
1995-05-05 |
1996-11-06 |
F. Hoffmann-La Roche Ag |
Recombinant obese (Ob) proteins
|
|
JPH11505706A
(ja)
*
|
1995-05-19 |
1999-05-25 |
イーライ・リリー・アンド・カンパニー |
肥満症遺伝子産物
|
|
JP2001501906A
(ja)
*
|
1995-05-26 |
2001-02-13 |
イーライ・リリー・アンド・カンパニー |
Ｒｈｅｓｕｓ ｏｂタンパク質およびｄｎａ
|
|
ZA965346B
(en)
*
|
1995-06-30 |
1997-12-24 |
Lilly Co Eli |
Methods of treating neuropeptide Y-associated conditions.
|
|
EP0759441A3
(en)
*
|
1995-06-30 |
1999-06-30 |
Eli Lilly And Company |
Methods of treating neuropeptide Y-associated conditions
|
|
CA2232193A1
(en)
*
|
1995-09-19 |
1997-03-27 |
Brigitte Elisabeth Schoner |
Dna encoding medicinal proteins
|
|
US6225446B1
(en)
|
1995-12-06 |
2001-05-01 |
Schering Corporation |
Mutational variants of mammalian proteins
|
|
AU1406497A
(en)
*
|
1995-12-06 |
1997-06-27 |
Schering Corporation |
Mutational variants of mammalian ob gene proteins
|
|
US6620413B1
(en)
|
1995-12-27 |
2003-09-16 |
Genentech, Inc. |
OB protein-polymer chimeras
|
|
US7074397B1
(en)
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
|
US6541604B1
(en)
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
|
EP0784981A3
(en)
*
|
1996-01-19 |
1999-03-03 |
Eli Lilly And Company |
Obesity protein formulations
|
|
AU1747297A
(en)
*
|
1996-01-19 |
1997-08-11 |
Eli Lilly And Company |
Obesity protein formulations
|
|
JP2000505079A
(ja)
*
|
1996-01-19 |
2000-04-25 |
イーライ・リリー・アンド・カンパニー |
肥満症タンパク質製剤
|
|
JP2000505791A
(ja)
*
|
1996-01-25 |
2000-05-16 |
イーライ・リリー・アンド・カンパニー |
肥満症タンパク質類似体化合物およびその製剤
|
|
WO1997028824A1
(en)
*
|
1996-02-06 |
1997-08-14 |
Eli Lilly And Company |
Obesity protein compounds and formulations thereof
|
|
IL125933A0
(en)
*
|
1996-03-01 |
1999-04-11 |
Amgen Inc |
Canine ob protein compositions and methods
|
|
EP0797999A3
(en)
*
|
1996-03-26 |
2002-09-25 |
Eli Lilly And Company |
Formulations of obesity protein
|
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
|
AU4160597A
(en)
*
|
1996-08-23 |
1998-03-06 |
Eli Lilly And Company |
Protein formulations
|
|
WO1998016545A1
(en)
*
|
1996-10-11 |
1998-04-23 |
Eli Lilly And Company |
Therapeutic proteins
|
|
AU5654998A
(en)
*
|
1996-12-06 |
1998-06-29 |
F. Hoffmann-La Roche Ag |
Muteins of obese protein
|
|
AU5901698A
(en)
*
|
1996-12-20 |
1998-07-17 |
Eli Lilly And Company |
Protein crystals, their preparation and use
|
|
CA2217698A1
(en)
*
|
1996-12-20 |
1998-06-20 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
CA2274799A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
CA2277282A1
(en)
*
|
1997-01-17 |
1998-07-23 |
Eli Lilly And Company |
Obesity protein formulations
|
|
US5965521A
(en)
*
|
1997-02-25 |
1999-10-12 |
Eli Lilly Company |
Pulsatile delivery of leptin receptor ligands
|
|
CA2282341A1
(en)
*
|
1997-02-25 |
1998-08-27 |
Eli Lilly And Company |
Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
|
|
WO1999023115A1
(en)
*
|
1997-10-31 |
1999-05-14 |
Eli Lilly And Company |
Glycosylated obesity protein analogs
|
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
WO2000024418A1
(en)
*
|
1998-10-27 |
2000-05-04 |
Eli Lilly And Company |
Prevention of muscle mass loss with leptin receptor ligands
|
|
MXPA04003773A
(es)
|
2001-10-22 |
2004-07-30 |
Amgen Inc |
Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
AU2004274309B2
(en)
|
2003-09-22 |
2010-04-08 |
Msd K.K. |
Novel piperidine derivative
|
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
|
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
|
CA2609388C
(en)
|
2005-05-30 |
2013-08-06 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
|
WO2007018248A1
(ja)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
ピリドン化合物
|
|
EP1921065B1
(en)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
|
CA2621470A1
(en)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
Bicyclic aromatic substituted pyridone derivative
|
|
US8227408B2
(en)
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
|
KR20080048502A
(ko)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
|
|
WO2007048027A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
|
US8158791B2
(en)
|
2005-11-10 |
2012-04-17 |
Msd K.K. |
Aza-substituted spiro derivatives
|
|
JP5489333B2
(ja)
|
2006-09-22 |
2014-05-14 |
メルク・シャープ・アンド・ドーム・コーポレーション |
脂肪酸合成阻害剤を用いた治療の方法
|
|
WO2008047544A1
(en)
|
2006-09-28 |
2008-04-24 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP2264026A4
(en)
|
2008-03-06 |
2012-03-28 |
Msd Kk |
ALKYLAMINOPYRIDINDERIVATE
|
|
EP2272841A1
(en)
|
2008-03-28 |
2011-01-12 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
|
CA2725143A1
(en)
|
2008-05-21 |
2009-11-26 |
Neurotez, Inc. |
Methods for treating progressive cognitive disorders related to neurofibrillary tangles
|
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
JPWO2009154132A1
(ja)
|
2008-06-19 |
2011-12-01 |
Ｍｓｄ株式会社 |
スピロジアミン−ジアリールケトオキシム誘導体
|
|
JP2011528375A
(ja)
|
2008-07-16 |
2011-11-17 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
|
MX2011004258A
(es)
|
2008-10-22 |
2011-06-01 |
Merck Sharp & Dohme |
Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2010054017A1
(en)
|
2008-11-04 |
2010-05-14 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
|
|
EP2379562A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
|
EP2416797A4
(en)
|
2009-04-10 |
2013-04-24 |
Amylin Pharmaceuticals Llc |
AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
|
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
EA032917B1
(ru)
*
|
2010-09-28 |
2019-08-30 |
Амилин Фармасьютикалс, Ллк |
Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
|
|
WO2012116145A1
(en)
|
2011-02-25 |
2012-08-30 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
CN103957926B
(zh)
|
2011-07-08 |
2018-07-03 |
安米林药品有限责任公司 |
具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
|
|
DE102012106607B4
(de)
|
2012-07-20 |
2024-04-04 |
Heliatek Gmbh |
Verfahren zur Versiegelung von Modulen mit optoelektronischen Bauelementen
|
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CA2898482A1
(en)
|
2013-02-22 |
2014-08-28 |
Linda L. Brockunier |
Antidiabetic bicyclic compounds
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2014274812B2
(en)
|
2013-06-05 |
2018-09-27 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US9708272B2
(en)
|
2014-08-29 |
2017-07-18 |
Tes Pharma S.R.L. |
Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
|
|
SI3509624T1
(sl)
|
2016-09-12 |
2023-12-29 |
Amryt Pharmaceuticals, Inc., |
Postopki detektiranja nevtralizirajočih protiteles proti leptinu
|
|
EP3526199B1
(en)
|
2016-10-14 |
2022-04-13 |
Tes Pharma S.r.l. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
MX2021005904A
(es)
|
2018-11-20 |
2021-09-08 |
Tes Pharma S R L |
Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
|
|
JP7526804B2
(ja)
*
|
2020-03-11 |
2024-08-01 |
エニジェン カンパニー リミテッド |
新規化合物を含む抗糖尿病及び抗肥満用組成物
|